Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward in targeting HBsAg ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Additionally, the IM-PROVE II Phase 2a trial showed that integrating low-dose nivolumab into imdusiran and Barinthus Biotherapeutics’ VTP-300 regimen heightened HBsAg loss rates. Data from this ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...